Otsuka Pharmaceutical Co., Ltd. has reported positive topline results from a randomized Phase 3b trial of centanafadine extended-release capsules in adults with attention-deficit/hyperactivity disorder and comorbid generalized anxiety disorder or social anxiety disorder. The investigational once-daily treatment improved ADHD symptoms against placebo over eight weeks, while also producing a statistically significant improvement on an anxiety measure, as centanafadine approaches a July 24, 2026 regulatory decision in the United States.
Why the comorbid anxiety population could strengthen centanafadine’s clinical positioning
The importance of this study lies less in confirming that centanafadine can reduce core ADHD symptoms and more in showing how the drug may perform in a population that is difficult to represent in conventional registration trials. Adults with ADHD frequently present with anxiety symptoms or a diagnosed anxiety disorder, yet psychiatric comorbidities can complicate treatment selection, response assessment and tolerability.
Clinicians must often distinguish between anxiety caused or amplified by untreated ADHD, an independent anxiety disorder and treatment-emergent symptoms such as insomnia, restlessness or increased physiological arousal. That complexity can make prescribers cautious about initiating or escalating ADHD medications, particularly when a patient already reports substantial anxiety.
Centanafadine’s performance in adults with generalized anxiety disorder, social anxiety disorder or both therefore gives Otsuka Pharmaceutical Co., Ltd. a potentially useful differentiation argument. The dataset suggests that ADHD symptom improvement was not prevented by the presence of clinically recognised anxiety and that anxiety scores did not worsen as a group. That is more commercially relevant than another narrowly controlled efficacy result in adults without significant psychiatric comorbidity.
However, the trial does not establish centanafadine as a treatment for anxiety disorders, nor does it show that the drug can replace dedicated anxiety therapies. The anxiety endpoint was secondary, the treatment period was short and the absolute placebo-adjusted difference was considerably smaller than the improvement recorded for ADHD symptoms. The results support a broader ADHD profile, but they should not be interpreted as proof of a dual-indication medicine.
What the ADHD and anxiety efficacy results reveal about the drug’s potential profile
The 315-patient study evaluated centanafadine extended release at 280 milligrams once daily against placebo. At week eight, the least-squares mean reduction in the Adult Investigator Symptom Rating Scale total score was 18.5 points with centanafadine and 12.6 points with placebo, producing a placebo-adjusted difference of 5.87 points and a p-value below 0.0001.
The numerical result appears consistent with an active ADHD medicine rather than a marginal statistical win. Separation from placebo was observed from week one and maintained through the eight-week trial, an important feature for a product that may be positioned as a nonstimulant alternative. Nonstimulant ADHD medicines can be perceived as slower to deliver noticeable benefits than stimulants, so evidence of early separation could become an important part of centanafadine’s clinical and commercial narrative.
The limitation is that a mean difference does not reveal how individual patients experienced treatment. Full data are still needed on responder rates, remission thresholds, functional improvement, discontinuations and the proportion of participants achieving changes that were meaningful in daily life. Mean symptom scores can conceal substantial variation, including patients who respond strongly, patients who gain little benefit and patients who stop treatment because of adverse events.
The Hamilton Anxiety Rating Scale result also requires measured interpretation. Centanafadine produced a 12.5-point mean reduction from baseline compared with a 10.6-point reduction for placebo, resulting in a placebo-adjusted difference of 1.92 points and a p-value of 0.02. The statistical result is positive, but the strong placebo response and relatively narrow between-group difference raise questions about the magnitude and clinical visibility of the anxiety benefit.
The anxiety finding may nevertheless matter if detailed results show that centanafadine reduced ADHD symptoms without destabilising anxiety across different patient subgroups. Regulators, clinicians and payers will want to see whether the effect was consistent in generalized anxiety disorder and social anxiety disorder, whether baseline anxiety severity influenced response and whether improvements were driven by reduced psychological symptoms, physical symptoms or broader functional gains.
How the Phase 3b design adds relevance while leaving important evidence gaps
The randomized, double-blind and placebo-controlled design provides a credible basis for evaluating efficacy over eight weeks. Enrolling adults aged 18 to 65 also extends the age range beyond the earlier pivotal adult studies, which evaluated participants aged 18 to 55. This may help Otsuka Pharmaceutical Co., Ltd. build a more representative evidence package for adult clinical practice.
The study also examined a defined comorbid population rather than relying on a post hoc subgroup extracted from a broader ADHD trial. Prospective enrolment allows the protocol to establish anxiety-related eligibility criteria, measure anxiety systematically and evaluate treatment under conditions designed specifically for the clinical question.
Even so, the study remains a short-term placebo-controlled trial. ADHD is a chronic condition, anxiety disorders can fluctuate over time and real-world patients may receive antidepressants, psychotherapy, stimulant medications or other psychiatric treatments concurrently. Trial restrictions on background therapies and substance use can create a cleaner efficacy signal while reducing generalisability to routine care.
The absence of an active comparator is another important limitation. The results do not establish whether centanafadine performs better than atomoxetine, viloxazine extended release, a stimulant or another commonly used treatment in adults with ADHD and anxiety. They show superiority to placebo under controlled conditions, which supports efficacy but does not settle where centanafadine should sit in treatment sequencing.
The fixed 280-milligram extended-release dose also creates questions that full publication should address. Otsuka’s earlier pivotal adult trials used 200-milligram and 400-milligram daily doses of a sustained-release formulation. Regulatory documents and eventual prescribing information will need to clarify the approved formulation, titration schedule, dose flexibility and relationship between the earlier and newer dosing regimens.
How centanafadine could compete with stimulant and nonstimulant ADHD therapies
Centanafadine inhibits the reuptake of norepinephrine, dopamine and serotonin, giving it a pharmacological profile that differs from currently marketed ADHD medicines. Stimulants primarily enhance catecholamine signalling and remain central to ADHD treatment because of their established efficacy and rapid action, but their controlled-substance status, misuse potential and tolerability profile can limit suitability for some patients.
Existing nonstimulant options include atomoxetine, guanfacine, clonidine and viloxazine extended release. These products provide alternatives for patients who do not respond to stimulants, cannot tolerate them, have substance-use concerns or require a different therapeutic approach. Centanafadine would enter a market where the existence of nonstimulants is already well established, meaning that novelty of mechanism alone will not guarantee adoption.
Its competitive case could rest on a combination of once-daily administration, early symptom improvement, efficacy across children, adolescents and adults, a potentially low abuse profile and evidence in patients with comorbid anxiety. A broad age indication would also allow clinicians and healthcare systems to use one product across multiple stages of ADHD care, although prescribing patterns and payer policies often vary considerably between pediatric and adult populations.
The serotonin component of centanafadine’s mechanism may attract particular attention because anxiety, emotional dysregulation and mood symptoms frequently overlap with adult ADHD. However, mechanistic plausibility must be separated from demonstrated clinical benefit. A triple reuptake profile could produce differentiation, but it could also create tolerability or interaction questions that only larger datasets and post-approval use can fully resolve.
Centanafadine’s eventual position may therefore be determined by practical outcomes rather than pharmacology alone. Prescribers will compare its onset, magnitude of benefit, cardiovascular effects, sleep impact, appetite effects, discontinuation rates and ease of titration with familiar alternatives. Payers will examine price, rebate structures and whether the drug delivers enough incremental value to justify preferred formulary access.
Why the tolerability findings could be as important as the efficacy signal
The most frequently reported adverse events occurring in more than 5% of centanafadine-treated participants and more frequently than with placebo included nausea, decreased appetite, diarrhea, insomnia, dry mouth and vomiting. These events are broadly compatible with the drug’s central monoamine activity, but their severity, duration and effect on treatment continuation remain undisclosed.
Several reported adverse events are especially relevant in ADHD treatment. Reduced appetite can affect weight and long-term adherence, while insomnia can worsen concentration, emotional regulation and anxiety symptoms. Gastrointestinal effects may be manageable during treatment initiation, but persistent nausea, diarrhea or vomiting could undermine the convenience of once-daily dosing.
The topline statement that safety was consistent with the known centanafadine profile provides reassurance about the absence of an immediately disclosed new safety signal, but it is not a substitute for detailed results. Industry observers will watch discontinuations due to adverse events, changes in blood pressure and heart rate, weight trajectories, psychiatric events and any differences between patients with generalized anxiety disorder and social anxiety disorder.
Longer-term evidence will also matter. A medicine used for chronic ADHD treatment must demonstrate that early efficacy can be maintained without an accumulating tolerability burden. Previous long-term centanafadine research provides useful support, but the comorbid anxiety population may have different medication sensitivities and higher rates of concurrent psychiatric treatment than adults enrolled in uncomplicated ADHD studies.
What the Phase 3b timing means for the July 2026 FDA decision
The United States Food and Drug Administration is reviewing centanafadine for ADHD in children, adolescents and adults, with a Prescription Drug User Fee Act target date of July 24, 2026. The application is supported principally by four pivotal Phase 3 trials across pediatric, adolescent and adult populations.
Because the new comorbid anxiety study was reported after the New Drug Application had entered Priority Review, it appears more likely to strengthen centanafadine’s broader evidence and post-approval positioning than to determine the core approvability decision. The regulator could consider late-cycle information where procedurally appropriate, but there is no confirmation that this Phase 3b study will influence the initial label.
An approval decision would still leave several commercially important questions unresolved. The final label will determine age coverage, dosing, titration, warnings, monitoring requirements and the claims Otsuka Pharmaceutical Co., Ltd. can use when communicating with healthcare professionals. Even a broad ADHD approval would not automatically permit a promotional claim involving comorbid anxiety.
A delay, restrictive label or request for additional information could weaken near-term launch momentum. Conversely, approval across children, adolescents and adults would give Otsuka Pharmaceutical Co., Ltd. a substantial platform from which to build the product, particularly if subsequent scientific presentations clarify centanafadine’s effects on anxiety, executive function and emotional dysregulation.
How centanafadine fits Otsuka’s neuroscience growth strategy and investor expectations
Centanafadine is strategically important because Otsuka Holdings Co., Ltd. has identified it among the pipeline assets expected to support the next stage of growth. The group is managing a transition in which newer products must offset maturity and loss-of-exclusivity pressures affecting established medicines. A successful ADHD launch would diversify Otsuka’s neuroscience portfolio and add a product with potential use across a large, chronic treatment market.
Investor sentiment toward Otsuka Holdings Co., Ltd., listed in Tokyo under ticker 4578, was already strong before the Phase 3b disclosure. The shares closed at 10,895 yen on June 26, 2026, up 0.51% for the session. The stock had gained approximately 3.7% over four weeks and about 53.7% over 12 months, while remaining below its 52-week high of 11,910 yen.
That performance suggests that expectations extend beyond centanafadine and reflect confidence in the wider portfolio, financial execution and pipeline. The ADHD asset can reinforce that sentiment if approved, but the market may already be assigning value to a positive regulatory outcome. This raises the sensitivity of the shares to label details, launch guidance and any unexpected regulatory setback.
Commercial success will not be immediate even after approval. Otsuka Pharmaceutical Co., Ltd. would need to secure formulary access, educate prescribers, establish differentiation from generic and branded alternatives and generate real-world evidence. The Phase 3b study supplies a potentially useful narrative, but adoption will depend on whether that narrative survives detailed scientific scrutiny and translates into practical prescribing advantages.
What clinicians, regulators and industry observers will watch next
The next major milestone is the July 24, 2026 regulatory target date, but the upcoming full presentation of the Phase 3b results may be almost as important for understanding the drug’s eventual clinical identity. Detailed data should clarify baseline characteristics, response distributions, completion rates, subgroup consistency and the precise nature of the anxiety improvement.
Particular attention will fall on whether centanafadine reduced anxiety independently of ADHD symptom improvement or whether better concentration, organisation and impulse control indirectly lowered anxiety scores. Both outcomes could be clinically valuable, but they imply different mechanisms and different expectations for practice.
The study strengthens centanafadine’s case as a potentially differentiated nonstimulant ADHD therapy. It does not yet prove superiority over existing options, establish an anxiety indication or answer the long-term safety and access questions that will determine commercial performance. For Otsuka Pharmaceutical Co., Ltd., the positive result adds useful depth to the product’s evidence base, but the FDA label, complete dataset and real-world adoption will decide whether centanafadine becomes a meaningful new treatment option or simply another entrant in an increasingly competitive ADHD market.
